The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Treatment rechallenge after trastuzumab-deruxtecan–related interstitial lung disease: A multi-institution cohort study.
 
Kelsey Natsuhara
No Relationships to Disclose
 
Kelly Blum
No Relationships to Disclose
 
Alexis LeVee
No Relationships to Disclose
 
Nikitha Vobugari
No Relationships to Disclose
 
Naomi Dempsey
Honoraria - Curio Science; Elsevier; Lilly; Novartis; OncLive/MJH Life Sciences; Precisca
Consulting or Advisory Role - Ashfield Healthcare; Gilead Sciences; Lilly; NeoGenomics Laboratories; Novartis; Pfizer
Speakers' Bureau - Seagen
Travel, Accommodations, Expenses - Gilead Sciences; Precisca
 
Sarah Premji
No Relationships to Disclose
 
Christina Moe
No Relationships to Disclose
 
Natasha Reddy
Employment - University of California, San Francisco
 
Jenna Hoppenworth
Consulting or Advisory Role - AstraZeneca
 
Maya Vella
No Relationships to Disclose
 
Laura Huppert
Consulting or Advisory Role - AstraZeneca; Pfizer
Research Funding - Greenwich LifeSciences (Inst)
Patents, Royalties, Other Intellectual Property - Book royalties: McGraw Hill
 
Anne Blaes
Research Funding - Dompé Farmaceutici
 
Jo Chien
Consulting or Advisory Role - Genentech/Roche
Research Funding - Amgen (Inst); Merck (Inst); Olema Oncology (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Seagen (Inst)
Patents, Royalties, Other Intellectual Property - Pending Patent Application for “COMBINATION INCLUDING A CPG-C TYPE OLIGONUCLEOTIDE AND A PD-1 ANTAGONIST FOR TREATING BREAST CANCER”
Travel, Accommodations, Expenses - Genentech/Roche
 
Michelle Melisko
Stock and Other Ownership Interests - Merrimack (I)
Consulting or Advisory Role - Genentech
Speakers' Bureau - AstraZeneca (I); Daiichi Sankyo/Astra Zeneca (I); Gilead Sciences (I)
Research Funding - DAEHWA Pharmaceutical (Inst); OBI Pharma (Inst); Puma Biotechnology (Inst)
Patents, Royalties, Other Intellectual Property - Multiple patents related to immunoliposomal drugs being studied and potentially brought to market by Merrimack (I)
Expert Testimony - GlaxoSmithKline
 
Geoffrey Buckle
Stock and Other Ownership Interests - Cardiff Oncology
Research Funding - Celgene
 
Joanne Mortimer
Consulting or Advisory Role - AstraZeneca; GE Healthcare; Pfizer
Research Funding - AstraZeneca
 
Dame Idossa
No Relationships to Disclose
 
Reshma Mahtani
Consulting or Advisory Role - Agendia; Amgen; Daiichi Sankyo/Astra Zeneca; Eisai; Genentech/Roche; Gilead Sciences; Hologic/Biotheranostics; Lilly; Merck; Novartis; Pfizer; Puma Biotechnology; Sanofi; Sermonix Pharmaceuticals; Stemline Therapeutics
Research Funding - Gilead Sciences (Inst)
Travel, Accommodations, Expenses - Agendia; Amgen; AstraZeneca; bioTheranostics; Daiichi Sankyo/Lilly; Eisai; Genentech/Roche; Lilly; Merck; Novartis; Pfizer; Puma Biotechnology; Sanofi; Seagen
 
Karthik Giridhar
Consulting or Advisory Role - AstraZeneca/Daiichi Sankyo (Inst); Exact Sciences (Inst); Gilead Sciences (Inst); Lilly (Inst); MJH Live Events (Inst); MJH Live Events (Inst); NeoGenomics Laboratories (Inst); Puma Biotechnology (Inst); Tersera (Inst)
Research Funding - Guardant Health (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - GRAIL; QuantumLeap Health
 
Hope Rugo
Honoraria - Chugai Pharma; Mylan/Viatris
Consulting or Advisory Role - Bristol Meyer; Napo Pharmaceuticals; Sanofi
Research Funding - Ambryx (Inst); AstraZeneca (Inst); Daiichi Sankyo (Inst); Gilead Sciences (Inst); Hoffmann-La Roche AG/Genentech, Inc (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); OBI Pharma (Inst); Pfizer (Inst); Stemline Therapeutics (Inst)